Sugi Predict

Sugi Predict / Compounds / SCHEMBL16294141

SCHEMBL16294141

SCHEMBL16294141

O=c1[nH]nc(Cl)c2cc(SCc3ccccc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ DAO P14920 5/20 0.48
▸ MAOB P27338 6/20 0.47
▸ MAOA P21397 3/20 0.47
▸ LMNA P02545 2/20 0.45
▸ PARP1 P09874 3/20 0.44
▸ AR P10275 1/20 0.43
▸ SCN9A Q15858 1/20 0.42
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16295073 0.95 DAO (0.48) DAOMAOBMAOALMNAPARP1
SCHEMBL28173425 0.82 DAO (0.48) DAOMAOBMAOALMNAPARP1
SCHEMBL17825233 0.81 PARP1 (0.64) DAOMAOBMAOALMNAPARP1
SCHEMBL17824806 0.80 PARP1 (0.50) DAOMAOBMAOALMNAPARP1
SCHEMBL17825205 0.79 DAO (0.45) DAOMAOBMAOALMNAPARP1
SCHEMBL17825353 0.78 CXCR2 (0.45) DAOMAOBMAOALMNAPARP1
SCHEMBL17824812 0.76 PARP1 (0.46) DAOMAOBMAOALMNAPARP1
SCHEMBL17824808 0.76 RAPGEF4 (0.46) DAOMAOBMAOALMNAPARP1
SCHEMBL15031982 0.76 PRMT5 (0.46) DAOMAOBMAOALMNAPARP1
SCHEMBL17824752 0.75 POLB (0.50) DAOKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-03-26 — — US disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 — — US disclosed
EP-3230273-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG Cancer Research Technology Ltd (GB) 2017-10-18 — — EP disclosed
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 — — US disclosed
WO-2016092326-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-16 — — WO disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 — — US disclosed
WO-2014201173-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2014-12-18 — — WO disclosed
WO-2014201173-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2014-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG PARG, PARP15, PARP12 DAO 862/4885MAOB 180/4885MAOA 267/4885
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG PARG, PARP15, PARP12 DAO 862/4885MAOB 180/4885MAOA 267/4885
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors SCN7A, SCN1A, SCN5A DAO 3805/4885MAOB 3348/4885MAOA 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.